Review



cd8a pe cy7  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Thermo Fisher cd8a pe cy7
    Changes in the Bone Marrow Immune Cell Content after 2-DG Stimulation. Note A Representative image (left) of ter119 + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. B Representative image (left) of Gr1 + CD11b + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. C Representative image (up) of CD4 + and <t>CD8</t> + T cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. D Quantitative data for CD4 + T cell proportion before and after 2-DG treatment in bone marrow are depicted. E Quantitative data for CD8 + T cell proportion before and after 2-DG treatment in bone marrow are provided as well. All experiments were conducted thrice. *** p < 0.001, ** p < 0.01, * p < 0.05
    Cd8a Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8a pe cy7/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    cd8a pe cy7 - by Bioz Stars, 2026-04
    86/100 stars

    Images

    1) Product Images from "Reprogramming hematopoietic stem cell metabolism in lung cancer: glycolysis, oxidative phosphorylation, and the role of 2-DG"

    Article Title: Reprogramming hematopoietic stem cell metabolism in lung cancer: glycolysis, oxidative phosphorylation, and the role of 2-DG

    Journal: Biology Direct

    doi: 10.1186/s13062-024-00514-w

    Changes in the Bone Marrow Immune Cell Content after 2-DG Stimulation. Note A Representative image (left) of ter119 + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. B Representative image (left) of Gr1 + CD11b + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. C Representative image (up) of CD4 + and CD8 + T cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. D Quantitative data for CD4 + T cell proportion before and after 2-DG treatment in bone marrow are depicted. E Quantitative data for CD8 + T cell proportion before and after 2-DG treatment in bone marrow are provided as well. All experiments were conducted thrice. *** p < 0.001, ** p < 0.01, * p < 0.05
    Figure Legend Snippet: Changes in the Bone Marrow Immune Cell Content after 2-DG Stimulation. Note A Representative image (left) of ter119 + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. B Representative image (left) of Gr1 + CD11b + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. C Representative image (up) of CD4 + and CD8 + T cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. D Quantitative data for CD4 + T cell proportion before and after 2-DG treatment in bone marrow are depicted. E Quantitative data for CD8 + T cell proportion before and after 2-DG treatment in bone marrow are provided as well. All experiments were conducted thrice. *** p < 0.001, ** p < 0.01, * p < 0.05

    Techniques Used: Flow Cytometry

    Changes in Splenic Immune Cell Content After 2-DG Stimulation. Notes A Effects of 2-DG treatment on spleen size (right) and body weight (left) in mice. B Representative flow cytometry analysis of the relative abundance of Ter119 + cells in the spleen before and after 2-DG treatment (left). Quantitative data are presented on the right. C Representative flow cytometry analysis of the relative abundance of CD11b + cells in the bone marrow before and after 2-DG treatment (left). Quantitative data are presented on the right. D Representative flow cytometry analysis of the relative abundance of Gr1 + cells in the bone marrow before and after 2-DG treatment (left). Quantitative data are presented on the right. E Representative flow cytometry analysis of the relative abundance of CD4 + T cells and CD8 + T cells in the bone marrow before and after 2-DG treatment. (F) Quantitative data on the proportion of CD4 + T cells in the spleen before and after 2-DG treatment. (G) Quantitative data on the percentage of CD8 + T cells in the spleen before and after 2-DG treatment. (H) Quantitative data on the percentage of B220 + cells in the spleen before and after 2-DG treatment. (n = 3; *** p < 0.001, ** p < 0.01, * p < 0.05)
    Figure Legend Snippet: Changes in Splenic Immune Cell Content After 2-DG Stimulation. Notes A Effects of 2-DG treatment on spleen size (right) and body weight (left) in mice. B Representative flow cytometry analysis of the relative abundance of Ter119 + cells in the spleen before and after 2-DG treatment (left). Quantitative data are presented on the right. C Representative flow cytometry analysis of the relative abundance of CD11b + cells in the bone marrow before and after 2-DG treatment (left). Quantitative data are presented on the right. D Representative flow cytometry analysis of the relative abundance of Gr1 + cells in the bone marrow before and after 2-DG treatment (left). Quantitative data are presented on the right. E Representative flow cytometry analysis of the relative abundance of CD4 + T cells and CD8 + T cells in the bone marrow before and after 2-DG treatment. (F) Quantitative data on the proportion of CD4 + T cells in the spleen before and after 2-DG treatment. (G) Quantitative data on the percentage of CD8 + T cells in the spleen before and after 2-DG treatment. (H) Quantitative data on the percentage of B220 + cells in the spleen before and after 2-DG treatment. (n = 3; *** p < 0.001, ** p < 0.01, * p < 0.05)

    Techniques Used: Flow Cytometry



    Similar Products

    pe cy7 tonbo biosciences 60 1886 u100 2 43 cd8b pacific blue biolegend 140414  (Cytek Biosciences)
    94
    Cytek Biosciences pe cy7 tonbo biosciences 60 1886 u100 2 43 cd8b pacific blue biolegend 140414
    Pe Cy7 Tonbo Biosciences 60 1886 U100 2 43 Cd8b Pacific Blue Biolegend 140414, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe cy7 tonbo biosciences 60 1886 u100 2 43 cd8b pacific blue biolegend 140414/product/Cytek Biosciences
    Average 94 stars, based on 1 article reviews
    pe cy7 tonbo biosciences 60 1886 u100 2 43 cd8b pacific blue biolegend 140414 - by Bioz Stars, 2026-04
    94/100 stars
    		  Buy from Supplier
    anti cd8 pe cy7  (Cytek Biosciences)
    93
    Cytek Biosciences anti cd8 pe cy7
    Anti Cd8 Pe Cy7, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd8 pe cy7/product/Cytek Biosciences
    Average 93 stars, based on 1 article reviews
    anti cd8 pe cy7 - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    anticd8 pe cy7  (Cytek Biosciences)
    93
    Cytek Biosciences anticd8 pe cy7
    Anticd8 Pe Cy7, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anticd8 pe cy7/product/Cytek Biosciences
    Average 93 stars, based on 1 article reviews
    anticd8 pe cy7 - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    pe cy7 labeled cd8a antibody  (Cytek Biosciences)
    93
    Cytek Biosciences pe cy7 labeled cd8a antibody
    Pe Cy7 Labeled Cd8a Antibody, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe cy7 labeled cd8a antibody/product/Cytek Biosciences
    Average 93 stars, based on 1 article reviews
    pe cy7 labeled cd8a antibody - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    tonbo cytek pe cy7 cd25 pc61 5  (Cytek Biosciences)
    90
    Cytek Biosciences tonbo cytek pe cy7 cd25 pc61 5
    Tonbo Cytek Pe Cy7 Cd25 Pc61 5, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tonbo cytek pe cy7 cd25 pc61 5/product/Cytek Biosciences
    Average 90 stars, based on 1 article reviews
    tonbo cytek pe cy7 cd25 pc61 5 - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    cd8α pe cy7  (Cytek Biosciences)
    93
    Cytek Biosciences cd8α pe cy7
    Cd8α Pe Cy7, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8α pe cy7/product/Cytek Biosciences
    Average 93 stars, based on 1 article reviews
    cd8α pe cy7 - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    pe cy7 anti mouse cd8a  (Cytek Biosciences)
    93
    Cytek Biosciences pe cy7 anti mouse cd8a
    a , 3D reconstructed images of H2087-LCC and M802T4-LCC cells disseminated in brain parenchyma at indicated time point after intracardiac inoculation into athymic mice and B6(Cg)-Tyrc-2J/J (B6-albino) mice, respectively. Cancer cells were visualized by GFP IF (green) and brain capillaries by CD31 IF (magenta). Scale bar: 10 μm. b , Quantification of elongated, spheroidal, and microclustered cancer cells (fewer than 10 cells) in A. n=33 and 18 for H2087-LCC cells on day7 and day 49 respectively. n=253 and 135 for M802T4-LCC cells on day 7 and day 49 respectively. Chi-square test. c , Representative images of H2087-LCC and M802T4-LCC cells expressing a TGF-β reporter in the lungs of athymic mice and B6129SF1/J mice, respectively, 7 weeks after intravenous injection. Cancer cells were visualized by GFP IF (green), the TGF-β mCherry reporter activity in red, Ki67 proliferation marker in white, and DAPI in blue. Scale bar: 20 μm. d , Quantification of TGF-β mCherry reporter and Ki67 expression in H2087-LCC (n=129) and M802T4-LCC (n=63) cells in the lungs of athymic and B6129SF1/J mice, respectively, 7 weeks after intravenous injection. e and f , Representative IF images of H2087-LCC in the lungs of athymic mice 7 weeks after intravenous injection. GFP + cancer cells (green), TGF-β mCherry reporter (red), E-cadherin or FN1 (white), and DAPI (blue). g , Quantification of TGF-β mCherry reporter and E-cadherin (n=87) or FN1 (n=53) expression in disseminated H2087-LCC cells in the lungs of athymic mice. h and i , Representative IF images of M802T4-LCC in the lungs of B6129SF1/J mice 7 weeks after intravenous injection. GFP + cancer cells (green), TGF-β mCherry reporter (red), E-cadherin (white), and DAPI (blue). Scale bar: 20 μm. j , Quantification of TGF-β mCherry reporter and E-cadherin (n=71) or FN1 (n=51) expression in M802T4-LCC in the lungs of B6129SF1/J mice 7 weeks after intravenous injection. k-m , Schematic representation of the experimental design, created with Biorender.com (k), and tracking of wild-type and Tgfbr2 KO M802T4-LCC cells intravenously inoculated in B6129SF1/J mice followed by antibody-mediated depletion of NK, CD4+ and <t>CD8+</t> T cells from day 3 (l) or day 35 (m) after inoculation. n=6 or 7 mice per group.
    Pe Cy7 Anti Mouse Cd8a, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe cy7 anti mouse cd8a/product/Cytek Biosciences
    Average 93 stars, based on 1 article reviews
    pe cy7 anti mouse cd8a - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier
    cd8a pe cy7  (Thermo Fisher)
    86
    Thermo Fisher cd8a pe cy7
    Changes in the Bone Marrow Immune Cell Content after 2-DG Stimulation. Note A Representative image (left) of ter119 + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. B Representative image (left) of Gr1 + CD11b + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. C Representative image (up) of CD4 + and <t>CD8</t> + T cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. D Quantitative data for CD4 + T cell proportion before and after 2-DG treatment in bone marrow are depicted. E Quantitative data for CD8 + T cell proportion before and after 2-DG treatment in bone marrow are provided as well. All experiments were conducted thrice. *** p < 0.001, ** p < 0.01, * p < 0.05
    Cd8a Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8a pe cy7/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    cd8a pe cy7 - by Bioz Stars, 2026-04
    86/100 stars
    		  Buy from Supplier
    cd8a pe-cy7  (Becton Dickinson)
    90
    Becton Dickinson cd8a pe-cy7
    Changes in the Bone Marrow Immune Cell Content after 2-DG Stimulation. Note A Representative image (left) of ter119 + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. B Representative image (left) of Gr1 + CD11b + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. C Representative image (up) of CD4 + and <t>CD8</t> + T cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. D Quantitative data for CD4 + T cell proportion before and after 2-DG treatment in bone marrow are depicted. E Quantitative data for CD8 + T cell proportion before and after 2-DG treatment in bone marrow are provided as well. All experiments were conducted thrice. *** p < 0.001, ** p < 0.01, * p < 0.05
    Cd8a Pe Cy7, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd8a pe-cy7/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    cd8a pe-cy7 - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    pe-cy7-conjugated rat anti-mouse cd8a  (Becton Dickinson)
    90
    Becton Dickinson pe-cy7-conjugated rat anti-mouse cd8a
    Changes in the Bone Marrow Immune Cell Content after 2-DG Stimulation. Note A Representative image (left) of ter119 + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. B Representative image (left) of Gr1 + CD11b + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. C Representative image (up) of CD4 + and <t>CD8</t> + T cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. D Quantitative data for CD4 + T cell proportion before and after 2-DG treatment in bone marrow are depicted. E Quantitative data for CD8 + T cell proportion before and after 2-DG treatment in bone marrow are provided as well. All experiments were conducted thrice. *** p < 0.001, ** p < 0.01, * p < 0.05
    Pe Cy7 Conjugated Rat Anti Mouse Cd8a, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe-cy7-conjugated rat anti-mouse cd8a/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    pe-cy7-conjugated rat anti-mouse cd8a - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a , 3D reconstructed images of H2087-LCC and M802T4-LCC cells disseminated in brain parenchyma at indicated time point after intracardiac inoculation into athymic mice and B6(Cg)-Tyrc-2J/J (B6-albino) mice, respectively. Cancer cells were visualized by GFP IF (green) and brain capillaries by CD31 IF (magenta). Scale bar: 10 μm. b , Quantification of elongated, spheroidal, and microclustered cancer cells (fewer than 10 cells) in A. n=33 and 18 for H2087-LCC cells on day7 and day 49 respectively. n=253 and 135 for M802T4-LCC cells on day 7 and day 49 respectively. Chi-square test. c , Representative images of H2087-LCC and M802T4-LCC cells expressing a TGF-β reporter in the lungs of athymic mice and B6129SF1/J mice, respectively, 7 weeks after intravenous injection. Cancer cells were visualized by GFP IF (green), the TGF-β mCherry reporter activity in red, Ki67 proliferation marker in white, and DAPI in blue. Scale bar: 20 μm. d , Quantification of TGF-β mCherry reporter and Ki67 expression in H2087-LCC (n=129) and M802T4-LCC (n=63) cells in the lungs of athymic and B6129SF1/J mice, respectively, 7 weeks after intravenous injection. e and f , Representative IF images of H2087-LCC in the lungs of athymic mice 7 weeks after intravenous injection. GFP + cancer cells (green), TGF-β mCherry reporter (red), E-cadherin or FN1 (white), and DAPI (blue). g , Quantification of TGF-β mCherry reporter and E-cadherin (n=87) or FN1 (n=53) expression in disseminated H2087-LCC cells in the lungs of athymic mice. h and i , Representative IF images of M802T4-LCC in the lungs of B6129SF1/J mice 7 weeks after intravenous injection. GFP + cancer cells (green), TGF-β mCherry reporter (red), E-cadherin (white), and DAPI (blue). Scale bar: 20 μm. j , Quantification of TGF-β mCherry reporter and E-cadherin (n=71) or FN1 (n=51) expression in M802T4-LCC in the lungs of B6129SF1/J mice 7 weeks after intravenous injection. k-m , Schematic representation of the experimental design, created with Biorender.com (k), and tracking of wild-type and Tgfbr2 KO M802T4-LCC cells intravenously inoculated in B6129SF1/J mice followed by antibody-mediated depletion of NK, CD4+ and CD8+ T cells from day 3 (l) or day 35 (m) after inoculation. n=6 or 7 mice per group.

    Journal: bioRxiv

    Article Title: TGF-β induces an atypical EMT to evade immune mechanosurveillance in lung adenocarcinoma dormant metastasis

    doi: 10.1101/2024.10.15.618357

    Figure Lengend Snippet: a , 3D reconstructed images of H2087-LCC and M802T4-LCC cells disseminated in brain parenchyma at indicated time point after intracardiac inoculation into athymic mice and B6(Cg)-Tyrc-2J/J (B6-albino) mice, respectively. Cancer cells were visualized by GFP IF (green) and brain capillaries by CD31 IF (magenta). Scale bar: 10 μm. b , Quantification of elongated, spheroidal, and microclustered cancer cells (fewer than 10 cells) in A. n=33 and 18 for H2087-LCC cells on day7 and day 49 respectively. n=253 and 135 for M802T4-LCC cells on day 7 and day 49 respectively. Chi-square test. c , Representative images of H2087-LCC and M802T4-LCC cells expressing a TGF-β reporter in the lungs of athymic mice and B6129SF1/J mice, respectively, 7 weeks after intravenous injection. Cancer cells were visualized by GFP IF (green), the TGF-β mCherry reporter activity in red, Ki67 proliferation marker in white, and DAPI in blue. Scale bar: 20 μm. d , Quantification of TGF-β mCherry reporter and Ki67 expression in H2087-LCC (n=129) and M802T4-LCC (n=63) cells in the lungs of athymic and B6129SF1/J mice, respectively, 7 weeks after intravenous injection. e and f , Representative IF images of H2087-LCC in the lungs of athymic mice 7 weeks after intravenous injection. GFP + cancer cells (green), TGF-β mCherry reporter (red), E-cadherin or FN1 (white), and DAPI (blue). g , Quantification of TGF-β mCherry reporter and E-cadherin (n=87) or FN1 (n=53) expression in disseminated H2087-LCC cells in the lungs of athymic mice. h and i , Representative IF images of M802T4-LCC in the lungs of B6129SF1/J mice 7 weeks after intravenous injection. GFP + cancer cells (green), TGF-β mCherry reporter (red), E-cadherin (white), and DAPI (blue). Scale bar: 20 μm. j , Quantification of TGF-β mCherry reporter and E-cadherin (n=71) or FN1 (n=51) expression in M802T4-LCC in the lungs of B6129SF1/J mice 7 weeks after intravenous injection. k-m , Schematic representation of the experimental design, created with Biorender.com (k), and tracking of wild-type and Tgfbr2 KO M802T4-LCC cells intravenously inoculated in B6129SF1/J mice followed by antibody-mediated depletion of NK, CD4+ and CD8+ T cells from day 3 (l) or day 35 (m) after inoculation. n=6 or 7 mice per group.

    Article Snippet: To validate the depletion of each immune population, peripheral blood was collected and stained with violetFluor 450 Anti-Mouse CD45 (30-F11) (Tonbo Biosciences, Cat# 75-0451-U100), FITC Anti-Mouse CD4 (GK1.5) (Tonbo Biosciences, Cat# 35-0041-U100), PE-Cy7 Anti-Mouse CD8a (53-6.7) (Tonbo Biosciences, Cat#60-0081-U100), APC Anti-Mouse NK1.1 (CD161) (PK136) (Tonbo Biosciences, Cat# 20-5941-U100), followed by flow cytometric analysis on an LSRFortessa (BD Biosciences) instrument.

    Techniques: Expressing, Injection, Activity Assay, Marker

    Changes in the Bone Marrow Immune Cell Content after 2-DG Stimulation. Note A Representative image (left) of ter119 + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. B Representative image (left) of Gr1 + CD11b + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. C Representative image (up) of CD4 + and CD8 + T cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. D Quantitative data for CD4 + T cell proportion before and after 2-DG treatment in bone marrow are depicted. E Quantitative data for CD8 + T cell proportion before and after 2-DG treatment in bone marrow are provided as well. All experiments were conducted thrice. *** p < 0.001, ** p < 0.01, * p < 0.05

    Journal: Biology Direct

    Article Title: Reprogramming hematopoietic stem cell metabolism in lung cancer: glycolysis, oxidative phosphorylation, and the role of 2-DG

    doi: 10.1186/s13062-024-00514-w

    Figure Lengend Snippet: Changes in the Bone Marrow Immune Cell Content after 2-DG Stimulation. Note A Representative image (left) of ter119 + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. B Representative image (left) of Gr1 + CD11b + cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. Quantitative data are presented on the right. C Representative image (up) of CD4 + and CD8 + T cell relative abundance in bone marrow before and after 2-DG treatment analyzed by flow cytometry. D Quantitative data for CD4 + T cell proportion before and after 2-DG treatment in bone marrow are depicted. E Quantitative data for CD8 + T cell proportion before and after 2-DG treatment in bone marrow are provided as well. All experiments were conducted thrice. *** p < 0.001, ** p < 0.01, * p < 0.05

    Article Snippet: The bone marrow cell suspension was then incubated with a series of specific surface antibodies, with Lin-FITC (#22-7770-72, eBioscience; https://www.thermofisher.cn/cn/zh/antibody/product/Mouse-Hematopoietic-Lineage-Antibody-clone-17A2-RA3-6B2-M1-70-TER-119-RB6-8C5-Cocktail/22-7770-72 ) labeling HSCs, Ter119-FITC marking erythroid cells (MA5-17821, eBioscience, https://www.thermofisher.cn/cn/zh/antibody/product/TER-119-Antibody-clone-TER119-Monoclonal/MA5-17821 ), Gr-1-APC (17-5931-82, eBioscience, https://www.thermofisher.cn/cn/zh/antibody/product/Ly-6G-Ly-6C-Antibody-clone-RB6-8C5-Monoclonal/17-5931-82 ), and CD11b-PE-Cy7 (557743, eBioscience, https://www.bdbiosciences.com/zh-cn/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/pe-cy-7-mouse-anti-human-cd11b.557743 ) labeling myeloid cells, and CD3-APC (17-0032-82, eBioscience, https://www.thermofisher.cn/cn/zh/antibody/product/CD3-Antibody-clone-17A2-Monoclonal/17-0032-82 ), CD4-PE (12-0041-82, eBioscience, https://www.thermofisher.cn/cn/zh/antibody/product/CD4-Antibody-clone-GK1-5-Monoclonal/12-0041-82 ), CD8a-PE-Cy7 (25-0081-82, eBioscience, https://www.thermofisher.cn/cn/zh/antibody/product/CD8a-Antibody-clone-53-6-7-Monoclonal/25-0081-82 ), and B220-PerCP-Cy5.5 (45-0452-82, eBioscience, https://www.thermofisher.cn/cn/zh/antibody/product/CD45R-B220-Antibody-clone-RA3-6B2-Monoclonal/45-0452-82 ) marking lymphoid cells.

    Techniques: Flow Cytometry

    Changes in Splenic Immune Cell Content After 2-DG Stimulation. Notes A Effects of 2-DG treatment on spleen size (right) and body weight (left) in mice. B Representative flow cytometry analysis of the relative abundance of Ter119 + cells in the spleen before and after 2-DG treatment (left). Quantitative data are presented on the right. C Representative flow cytometry analysis of the relative abundance of CD11b + cells in the bone marrow before and after 2-DG treatment (left). Quantitative data are presented on the right. D Representative flow cytometry analysis of the relative abundance of Gr1 + cells in the bone marrow before and after 2-DG treatment (left). Quantitative data are presented on the right. E Representative flow cytometry analysis of the relative abundance of CD4 + T cells and CD8 + T cells in the bone marrow before and after 2-DG treatment. (F) Quantitative data on the proportion of CD4 + T cells in the spleen before and after 2-DG treatment. (G) Quantitative data on the percentage of CD8 + T cells in the spleen before and after 2-DG treatment. (H) Quantitative data on the percentage of B220 + cells in the spleen before and after 2-DG treatment. (n = 3; *** p < 0.001, ** p < 0.01, * p < 0.05)

    Journal: Biology Direct

    Article Title: Reprogramming hematopoietic stem cell metabolism in lung cancer: glycolysis, oxidative phosphorylation, and the role of 2-DG

    doi: 10.1186/s13062-024-00514-w

    Figure Lengend Snippet: Changes in Splenic Immune Cell Content After 2-DG Stimulation. Notes A Effects of 2-DG treatment on spleen size (right) and body weight (left) in mice. B Representative flow cytometry analysis of the relative abundance of Ter119 + cells in the spleen before and after 2-DG treatment (left). Quantitative data are presented on the right. C Representative flow cytometry analysis of the relative abundance of CD11b + cells in the bone marrow before and after 2-DG treatment (left). Quantitative data are presented on the right. D Representative flow cytometry analysis of the relative abundance of Gr1 + cells in the bone marrow before and after 2-DG treatment (left). Quantitative data are presented on the right. E Representative flow cytometry analysis of the relative abundance of CD4 + T cells and CD8 + T cells in the bone marrow before and after 2-DG treatment. (F) Quantitative data on the proportion of CD4 + T cells in the spleen before and after 2-DG treatment. (G) Quantitative data on the percentage of CD8 + T cells in the spleen before and after 2-DG treatment. (H) Quantitative data on the percentage of B220 + cells in the spleen before and after 2-DG treatment. (n = 3; *** p < 0.001, ** p < 0.01, * p < 0.05)

    Article Snippet: The bone marrow cell suspension was then incubated with a series of specific surface antibodies, with Lin-FITC (#22-7770-72, eBioscience; https://www.thermofisher.cn/cn/zh/antibody/product/Mouse-Hematopoietic-Lineage-Antibody-clone-17A2-RA3-6B2-M1-70-TER-119-RB6-8C5-Cocktail/22-7770-72 ) labeling HSCs, Ter119-FITC marking erythroid cells (MA5-17821, eBioscience, https://www.thermofisher.cn/cn/zh/antibody/product/TER-119-Antibody-clone-TER119-Monoclonal/MA5-17821 ), Gr-1-APC (17-5931-82, eBioscience, https://www.thermofisher.cn/cn/zh/antibody/product/Ly-6G-Ly-6C-Antibody-clone-RB6-8C5-Monoclonal/17-5931-82 ), and CD11b-PE-Cy7 (557743, eBioscience, https://www.bdbiosciences.com/zh-cn/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/pe-cy-7-mouse-anti-human-cd11b.557743 ) labeling myeloid cells, and CD3-APC (17-0032-82, eBioscience, https://www.thermofisher.cn/cn/zh/antibody/product/CD3-Antibody-clone-17A2-Monoclonal/17-0032-82 ), CD4-PE (12-0041-82, eBioscience, https://www.thermofisher.cn/cn/zh/antibody/product/CD4-Antibody-clone-GK1-5-Monoclonal/12-0041-82 ), CD8a-PE-Cy7 (25-0081-82, eBioscience, https://www.thermofisher.cn/cn/zh/antibody/product/CD8a-Antibody-clone-53-6-7-Monoclonal/25-0081-82 ), and B220-PerCP-Cy5.5 (45-0452-82, eBioscience, https://www.thermofisher.cn/cn/zh/antibody/product/CD45R-B220-Antibody-clone-RA3-6B2-Monoclonal/45-0452-82 ) marking lymphoid cells.

    Techniques: Flow Cytometry